KOD vs OCUL vs BEAM vs ARWR vs EDIT

For growth investors, Arrowhead Pharmaceuticals, Inc.

(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus -100. 0% for Editas Medicine, Inc. (EDIT). Analysts rate Kodiak Sciences Inc. (KOD) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Kodiak Sciences Inc.

(KOD) delivered a total return of +115. 0%, compared to -91. 1% for Editas Medicine, Inc. (EDIT). Over 10 years, the gap is even starker: KOD returned +1920% versus EDIT's -89. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ocular Therapeutix, Inc.

(OCUL) is the lower-risk stock at 1. 11β versus Editas Medicine, Inc. 's 2. 45β — meaning EDIT is approximately 120% more volatile than OCUL relative to the S&P 500. On balance sheet safety, Ocular Therapeutix, Inc. (OCUL) carries a lower debt/equity ratio of 12% versus 73% for Arrowhead Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.

(ARWR) is pulling ahead at 232. 6% versus -100. 0% for Editas Medicine, Inc. (EDIT). On earnings-per-share growth, the picture is similar: Arrowhead Pharmaceuticals, Inc. grew EPS 99. 8% year-over-year, compared to -16. 4% for Ocular Therapeutix, Inc.. Over a 3-year CAGR, ARWR leads at 50. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Kodiak Sciences Inc.

(KOD) is the more profitable company, earning 0. 0% net margin versus -513. 2% for Ocular Therapeutix, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARWR leads at 11. 9% versus -521. 0% for OCUL. At the gross margin level — before operating expenses — ARWR leads at 97. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Kodiak Sciences Inc.

(KOD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+1920% 10Y return). Editas Medicine, Inc. (EDIT) carries a higher beta of 2. 45 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KOD: +1920%, EDIT: -89. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KOD is a small-cap quality compounder stock; OCUL is a small-cap quality compounder stock; BEAM is a small-cap high-growth stock; ARWR is a mid-cap high-growth stock; EDIT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.